VINRKLB.BO · BSE

REKVINA LABORATORIES LTD.

₹50.91

-1.98% (-₹1.03)

Prev. close

₹51.94

Volume

1,495

As of

24 Sept 2026

Price history

₹50.91+₹12.69 (+33.20%) · 3M
15 Jun 2026 → 24 Sept 2026
₹59.4₹2515 Jun14 Jul10 Aug01 Sept24 Sept
Daily closes · updates after each session

No analyst calls on this stock in the last 90 days yet.

Explore by date range →

Analyst opinions

No analyst calls on REKVINA LABORATORIES LTD. in the last 90 days.

Fundamentals

About REKVINA LABORATORIES LTD.

Rekvina Laboratories Limited engages in manufacturing and marketing pharmaceutical products in India. It offers pharmaceutical formulations. The company also provides contract research and manufacturing services. Rekvina Laboratories Limited was incorporated in 1988 and is based in Vadodara, India.

Details

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Mr. Surbhit Mukeshbhai Shah

Headquarters

Vadodara

Employees

5

Key stats

Market cap

₹57.74 Cr

EPS (TTM)

₹-0.56

Beta (1Y · daily vs NIFTY 50)

-0.15

Beta (5Y · monthly vs NIFTY 50)

-1.60

Shares float

12.56 L

EPS · quarter ended Jun 2026

₹-0.20

Financial Performance

01 · Financials

-1 Cr0 Cr1 Cr2 Cr₹FY23FY24FY25FY26
RevenueNet incomeEBITDA

02 · Earnings Per Share (EPS)

-1-0-00₹FY23FY24FY25FY26

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based · pre-FY23 not filed in verifiable form

-100%-75%-50%-25%0%FY23FY24FY25

05 · Capital Structure & Asset Utilization

Pre-FY23 not filed in verifiable form

0 Cr0.5 Cr1 Cr1.5 Cr₹0×2.5×5×7.5×FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Debt/equity omitted where reported equity was zero or negative. Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

Pre-FY23 not filed in verifiable form

0 Cr0.5 Cr1 Cr1.5 Cr₹FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

Other assets floored at zero for years where fixed and current assets exceeded reported total assets.

07 · Debt Level & Coverage

Pre-FY23 not filed in verifiable form

-1 Cr0 Cr1 Cr2 Cr₹FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY22FY23FY24FY25FY26
—₹0₹0₹0₹1.27 Cr
EBITDA—₹-41,000₹-1.64 L₹-13.71 L₹-25.50 L
—₹-7,000₹-1.64 L₹-13.71 L₹-25.50 L
Diluted EPS—₹-0₹-0.03₹-0.23₹-0.42

Revenue, Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, Other expenses, EBITDA, Net income, Pretax income, Tax provision, Interest expense, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

09 · Balance Sheet

Annual

Line itemFY22FY23FY24FY25FY26
—₹20.17 L₹95,000₹3.25 L₹1.19 Cr
—₹8.14 L₹3.95 L₹24.69 L₹1.47 Cr
Stockholders' equity—₹1.32 L₹-19.52 L₹-33.22 L₹-1.23 Cr

Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated. Inventory shows ₹0 for 2022-03-31, 2023-03-31, 2024-03-31 — this deck's own annual-report reading has no Inventory figure for this filer in any year shown (2022-03-31, 2023-03-31, 2024-03-31, 2025-03-31, 2026-03-31 alike); the ₹0 shown here comes from this filer's own reported data feed rather than this deck's own extraction, and is positively consistent with a filer that holds no physical inventory (typical for lenders and other financial-services companies) rather than a display default. 2025-03-31, 2026-03-31 have no Inventory figure reaching this deck at all — not shown as zero, not shown as positive — left blank rather than assumed to match the other years.

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY22FY23FY24FY25FY26
—₹99,000₹-84,000₹-19.19 L₹-59.43 L
Investing cash flow—₹0₹0₹0₹0
—₹-4,000₹81,000₹20.74 L₹58.46 L
End cash position—₹98,000₹95,000₹2.50 L₹1.54 L

Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source has no quarterly cash-flow-statement coverage.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.47 L Cr₹1,849.937.05.3513.7%0.06+11.9%+13.7%
Divi's Laboratories Limited₹2.55 L Cr₹9,60287.215.2415.3%0.00+12.3%+60.5%
Torrent Pharmaceuticals Limited₹1.90 L Cr₹4,928.579.522.6025.8%1.79+21.5%+36.3%
Apollo Hospitals Enterprise Limited₹1.30 L Cr₹8,888.561.013.7520.5%0.90+15.7%+16.3%
Lenskart Solutions Limited₹1.19 L Cr₹676180.713.615.6%0.35+35.4%—
Zydus Lifesciences Limited₹1.17 L Cr₹1,180.326.14.3118.6%0.46+18.4%+13.9%
Cipla Limited₹1.12 L Cr₹1,39933.23.2411.3%0.02+2.1%-9.0%
Laurus Labs Limited₹1.10 L Cr₹2,026.2100.920.8416.8%0.48+22.0%+122.7%
Max Healthcare Institute Limited₹1.03 L Cr₹1,04671.19.6013.4%0.32+19.0%-7.7%
Mankind Pharma Limited₹1.02 L Cr₹2,50049.06.2511.7%0.39+17.0%-1.2%
Dr. Reddy's Laboratories Limited₹1.01 L Cr₹1,200.430.52.6811.4%0.21+3.2%-7.5%
REKVINA LABORATORIES LTD.₹57.74 Cr₹51.94——————

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

Documents

VINRKLB.BO

Rekvina Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Rekvina Laboratories Limited reported a net loss of INR 1.21 million for the first quarter ended June 30, 2026, compared to INR 0.354 million a year ago. Sales and revenue for the quarter were INR 6.69 million. Basic and diluted loss per share from continuing operations both increased to INR 0.2.